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We evaluated the hemodynamics and outcomes of septic shock (SS) patients who did not respond to 
ﬂuid resuscitation,  after treatment with or without intravenous calcium.  We retrospectively collected 
information on 154 eligible SS patients who were admitted to Fukuyama City Hospital Emergency 
Medical Center and did not respond to ﬂuid resuscitation.  To compare their degree of hemodynamic 
impairment,  we compared the changes in the vasoactive-inotropic score (VIS) in the calcium-treated 
group (n＝112) and the noncalcium-treated group (n＝42).  We compared the length of stay in the inten-
sive care unit (ICU) and hospital,  in-hospital deaths,  28-day deaths,  and changes in the Sequential 
Organ Failure Assessment score within 72h of ICU admission between the 2 groups.  Changes in the 
VIS at 1h after the baseline time were signiﬁcantly greater in the calcium-treated group than in the 
noncalcium-treated group (1.41 vs. －1.25,  respectively; p＜0.001).  However,  the changes in the VIS at 
3,  6,  24,  48,  and 72h did not diﬀer between the 2 groups.  The secondary outcomes also did not diﬀer 
between the groups.  Our ﬁndings indicate that calcium administered to SS patients might reduce their 
hemodynamic stabilization,  but only for a short time after its administration.
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evere sepsis and septic shock cause high mor-
tality in intensive care units (ICUs) [1,  2].  
Although potent antibiotics and procedures have been 
developed for these diseases,  the mortality rate is 
currently 30-50ｵ in patients with severe sepsis and 
can exceed 50ｵ in septic shock (SS) patients [3].  
The incidence of patients with severe sepsis is also 
increasing [4,  5].  Guidelines for the management of 
severe sepsis and septic shock have not been well 
established,  and the development of eﬀective strate-
gies for the treatment of SS patients is an important 
issue worldwide [6].
　 It has been reported that the concentration of ion-
ized calcium is reduced in septic patients and that this 
reduction is associated with the severity of sepsis and 
patient mortality [7,  8].  A paper has also suggested 
that the administration of calcium reduces the doses of 
inotropic and vasopressor agents required by critically 
ill patients with ionized hypocalcemia,  by increasing 
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the myocardial contractility and vascular tonus [9].  In 
animal model studies,  the administration of calcium 
increased the mortality of septic rats [10],  whereas 
it improved sepsis-related myocardial suppression with 
no deleterious events [11].  Human studies have shown 
no beneﬁts of calcium administration to septic patients 
[12,  13].  The eﬀectiveness of calcium administration 
to septic patients thus remains unclear.
　 In the Emergency Medical Center of Fukuyama 
City Hospital,  intravenous calcium is sometimes 
administered to SS patients with ionized hypocalcemia 
who are receiving inotropic and/or vasopressor agents.  
This retrospective study assessed the hemodynamics 
and outcomes of SS patients treated with or without 
intravenous calcium.
Subjects and Methods
　 Study subjects. This was a retrospective,  
single-center study.  We enrolled SS patients who had 
been admitted to the Emergency Medical Center of 
Fukuyama City Hospital and were administered intra-
venous catecholamine.  The catecholamine,  predomi-
nantly dopamine or noradrenaline,  was administered 
to those SS patients who did not respond to ﬂuid 
resuscitation.  The observational period was from 
April 1,  2005 to March 31,  2013.  The study proto-
col was approved by the Institutional Review Board of 
Fukuyama City Hospital.
　 Setting and data collection. Fukuyama City 
Hospital,  located in the eastern area of Hiroshima 
Prefecture,  Japan,  has 506 beds and 7 regular inten-
sivists in its Emergency Medical Center (24 beds in 
the ICU).  In the ICU,  the attending doctors from each 
department are responsible for the treatment of their 
patients in collaboration with the intensivists.  
Approximately 1,400 patients are admitted to this 
center every year,  and 60 of them had sepsis during 
the study period.  Intravenous calcium was adminis-
tered to the SS patients receiving a catecholamine 
based on the judgment of the attending physicians 
and/or intensivists.
　 In accordance with the deﬁnition of the American 
College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference Committee [14,  15],  
we deﬁned sepsis as a systemic inﬂammatory response 
to infection; we deﬁned severe sepsis as sepsis associ-
ated with organ dysfunction,  hypoperfusion,  or 
hypotension,  and we deﬁned septic shock as severe 
sepsis with persistent hypotension (systolic blood 
pressure＜90mmHg or a reduction ofｧ40mmHg 
from baseline),  associated with organ perfusion abnor-
malities that were not improved by ﬂuid resuscitation,  
or with normotension sustained by inotropic or vaso-
pressor agents.  The SS patients were treated accord-
ing to the guidelines for the management of severe 
sepsis and septic shock [6,  16,  17].
　 The exclusion criteria for this study were:  
children aged＜18 years,  pregnant women,  patients 
with burns,  terminally ill patients (do-not-attempt-
resuscitation),  and patients with postcardiac arrest,  
neutropenia caused by chemotherapy,  a history of 
organ transplantation,  or nonseptic shock (e.g.,  ana-
phylactic shock) within 72h of admission.  Patients 
without data on the dose of catecholamine within 72h 
after admission were also excluded.
　 Information on the characteristics and outcomes of 
the SS patients was extracted retrospectively from 
their medical records,  including age,  sex,  the Acute 
Physiology and Chronic Health Evaluation (APACHE) 
II score [18],  the Sequential Organ Failure Assessment 
(SOFA) score [19],  the type and dose of inotropic 
and vasopressor agents given,  mean arterial pressure,  
intravenous calcium administered,  laboratory data at 
ICU admission (white blood cell count,  concentrations 
of ionized calcium,  sodium,  potassium,  and creati-
nine),  24-h urine volume,  renal replacement therapy,  
transfusion of red cell concentrate,  fresh frozen 
plasma,  or platelet concentrate,  corticosteroid ther-
apy,  treatment for disseminated intravascular coagu-
lation,  the time interval from admission to calcium 
administration,  the lengths of ICU and hospital stays,  
in-hospital death,  and 28-day death.
　 Among the SS patients who received a cate-
cholamine,  we deﬁned those who were administered 
intravenous calcium within 24h of admission as the 
“calcium-treated group,” and those who were not 
administered intravenous calcium within 24h of admis-
sion as the “noncalcium-treated group.”
　 Study endpoints. The primary endpoint was 
the change in the vasoactive-inotropic score (VIS) 
[20],  an index of the required amount of hemody-
namic support,  which can be used as a surrogate for 
the degree of hemodynamic impairment.  A higher VIS 
indicates a greater vasopressor requirement.  We were 
therefore able to assess the hemodynamic diﬀerences 
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among the SS patients treated with or without intra-
venous calcium by comparing the changes in their 
VISs.  The formulae for the VIS and inotropic score 
are:
　VIS＝inotropic score＋10×milrinone dose (µg/
kg/min)＋10,000×vasopressin dose (U/kg/min)＋
100×noradrenaline dose (µg/kg/min) [20]
　 Inotropic score＝dopamine dose＋dobutamine dose
＋100×adrenaline dose (all doses in µg/kg/min) [21]
The secondary endpoints were the lengths of ICU and 
hospital stays,  in-hospital deaths,  28-day deaths,  and 
the change in the SOFA score 72h after ICU admis-
sion.
　 Statistical analysis. The patient characteris-
tics and outcomes of the 2 groups (i.e.,  the groups with 
and without intravenous calcium) were compared.  
Continuous variables are presented as means and 95ｵ 
conﬁdence intervals (CIs),  and diﬀerences were ana-
lyzed with the Mann-Whitney U-test; categorical 
variables are expressed in percentages (n/N),  and 
diﬀerences were analyzed with the χ2 test or Fischerʼs 
exact test.  We compared changes in the VIS values of 
the 2 groups at 1,  3,  6,  24,  48,  and 72h from base-
line.  We deﬁned the baseline as the time at which 
intravenous calcium was administered for the ﬁrst 
time (the calcium-treated group) or when the patient 
was admitted to the ICU (the noncalcium-treated 
group),  because the patientʼs hemodynamic condition 
would be most unstable at the baseline.  All data were 
analyzed with SPSS Statistics software,  version 
21.0J (IBM Corp.  Armonk,  NY,  USA).  Two-sided 
p-values＜0.05 were considered signiﬁcant,  and we 
also used the Bonferroni correction method to correct 
the problem of multiple comparisons for changes in the 
VIS values of the 2 groups.
Results
　 Between April 2005 and March 2013,  452 septic 
patients were admitted to the Emergency Medical 
Center of Fukuyama City Hospital (Fig.  1).  We 
excluded 181 patients who were not in shock,  65 who 
did not receive a catecholamine within 72h of ICU 
admission,  42 who did not meet our inclusion criteria,  
and 10 who had no available data on the dose of cate-
cholamine.  Therefore,  154 SS patients who were 
199Calcium for Septic Shock PatientsAugust 2015
Septic patients admitted to
Fukuyama City Hospital Emergency
Medical Center from April 1, 2005
to March 31, 2013
n = 452
No shock patients n = 181
Septic patients not administered catecholamine within
72 h of ICU admission n = 65
Did not meet our criteria n = 42
Burn n = 16
DNAR n = 9
CPA n = 8
Other shock n = 5
Child n = 1
Other n = 3
Septic shock patients who received
catecholamine n = 164 
No available data on the dose of catecholamine n = 10
Eligible patients
n = 154
Calcium-treated group
n = 112
Noncalcium-treated group
n = 42
Fig. 1　 Patient ﬂow.  ICU,  intensive care unit; DNAR,  do-not-attempt-resuscitation; CPA,  cardiopulmonary arrest.
administered a catecholamine (112 in the calcium-
treated group and 42 in the noncalcium-treated group) 
were eligible for our analysis.
　 Table 1 shows the characteristics of the SS 
patients who received a catecholamine,  with or with-
out intravenous calcium,  at ICU admission.  There 
were no signiﬁcant diﬀerences in the age or sex of the 
2 groups.  The dose of vasopressin (0.008 vs. 0.003 
units/min,  respectively; p＝0.032),  the requirement 
for fresh frozen plasma (11.0 vs. 7.3 units,  
respectively; p＝0.013),  and platelet concentrate (8.8 
vs. 3.4 units,  respectively; p＝0.032) were signiﬁ-
cantly higher in the calcium-treated group than in the 
noncalcium-treated group,  and the number of white 
blood cells was signiﬁcantly lower in the calcium-
treated group (11,900 vs. 15,400/µL,  respectively;  
p＝0.012).  However,  all other factors were almost 
identical between the 2 groups.  In the calcium-treated 
group,  the mean time interval from ICU admission to 
calcium administration was 3.3h.
　 To compare the degree of hemodynamic impairment 
in the 2 groups,  we compared the changes in VIS at 
1,  3,  6,  24,  48,  and 72h from baseline (Table 2).  
The VIS values at baseline were similar in the cal-
cium- and noncalcium-treated groups (7.10 vs. 7.08,  
respectively; p＝0.872).  The change in the VIS at 1h 
from baseline was signiﬁcantly greater in the calcium-
treated group than in the noncalcium group (1.41 vs. 
－1.25,  respectively; p＜0.001).  This p-value was 
still signiﬁcant when the Bonferroni correction tested 
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Table 1　 Characteristics of septic shock patients treated with a catecholamine with or without intravenous calcium administration at ICU 
admission
Calcium-treated group
(n＝112)
Noncalcium-treated group 
(n＝42) P value
Age,  y 72 (70-74) 74 (71-78) 0.320
Men,  no. (%) 73 65.2 24 57.1 0.358
APACHE II score 33.5 (32.1-34.9) 30.5 (28.0-32.9) 0.068
SOFA score＊ 11.5 (10.8-12.1) 10.4 (9.3-11.4) 0.094
Mean arterial pressure,  mmHg† 68.1 (64.9-71.3) 74.3 (67.8-80.9) 0.234
Noradrenaline,  µg/kg/min† 0.017 (0.007-0.027) 0.014 (0.001-0.027) 0.792
Dopamin,  µg/kg/min† 3.7 (3.0-4.5) 4.7 (3.0-6.4) 0.433
Vasopressin,  units/min† 0.008 (0.005-0.010) 0.003 (0.000-0.006) 0.032
Inotropic score† 3.91 (3.16-4.66) 5.12 (3.36-6.88) 0.326
Laboratory data
　White blood cell count,  1,000/µL 11.9 (10.0-13.9) 15.0 (12.1-17.8) 0.024
　Ionized calcium,  mmol/L 1.12 (1.11-1.14) 1.15 (1.12-1.17) 0.181
　Sodium,  mmol/L 133 (132-134) 133 (131-135) 0.889
　Potassium,  mmol/L 3.8 (3.7-4.0) 3.9 (3.7-4.0) 0.748
　Creatinine,  mg/dL 2.2 (1.9-2.5) 2.1 (1.1-3.2) 0.083
Diuresis,  mL/24h 3,473 (2,845-4,101) 3,878 (2,927-4,829) 0.238
Renal replacement therapy,  no. (%) 36 32.1 10 23.8 0.314
Transfusion‡
　RCC,  units 2.7 (2.0-3.4) 1.7 (0.8-2.5) 0.103
　FFP,  units 11.0 (8.9-13.1) 5.3 (2.8-7.8) 0.002
　PC,  units 8.8 (6.1-11.4) 3.4 (1.0-5.8) 0.032
Corticosteroids,  no. (%) 43 38.4 14 33.3 0.562
DIC therapy,  no. (%) 81 72.3 25 59.5 0.127
Time interval from ICU admission to calcium administration,  hours 3.3 (2.5-4.1) - -
ICU denotes Intensive Care Unit; APACHE II,  acute physiology and chronic health evaluation II; SOFA,  sequential organ failure 
assessment; RCC,  red cell concentrate; FFP,  fresh frozen plasma; PC,  platelet concentrate; DIC,  disseminated intravascular coagula-
tion.  Data are means (95% conﬁdence interval).
＊The SOFA score was missing for 28 patients in the calcium-treated group and 14 in the noncalcium-treated group.
†These values in the calcium-treated group were obtained when intravenous calcium was administered initially after ICU admission.
‡Total transfusion units within 72h after ICU admission.
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The changes in the VIS at 3,  6,  24,  48,  and 72h did 
not diﬀer between the 2 groups.
　 The secondary outcomes,  i.e.,  the lengths of the 
ICU and hospital stays,  in-hospital deaths,  28-day 
deaths,  and changes in the SOFA score 72h after 
ICU admission,  did not diﬀer between the 2 groups 
(Table 3).
Discussion
　 The results of this retrospective single-center 
study demonstrated that the changes in VIS among SS 
patients at 1h from baseline were signiﬁcantly greater 
in the patients treated with calcium compared to the 
no-calcium group,  whereas the changes in the VIS at 
3,  6,  24,  48,  and 72h were similar between the 2 
groups.  These results suggest that the administration 
of calcium temporarily increases the requirement for 
inotropic and vasopressor agents in SS patients and 
has a deleterious eﬀect on their hemodynamic stabili-
zation.
　 The guidelines for the management of severe sepsis 
and septic shock do not recommend the routine use of 
pulmonary artery catheters for SS patients [6],  and 
information on these patientsʼ hemodynamics,  including 
the cardiac index and the systemic vascular resistance 
index (which are measured directly from the pulmo-
nary catheter) is not available for most SS patients.  
Therefore,  unlike previous studies,  we assessed the 
hemodynamics of SS patients who were treated with 
or without intravenous calcium by using the VIS,  
calculated from the patientsʼ requirement for inotropic 
and vasopressor agents.  The VIS was originally 
developed as an index of cardiovascular support during 
the perioperative period among infants who underwent 
congenital heart surgery [20] and was also used to 
assess the hemodynamics of adult patients receiving 
cardiac surgery [22].
　 Vasoactive agents such as vasopressin and milri-
none are now available for the management of patients 
with severe sepsis or septic shock [6,  16,  17,  23],  
and we therefore assessed the hemodynamics in SS 
patients by using the VIS,  which can reﬂect the inﬂu-
ence of these drugs.  We thus believe that the present 
studyʼs ﬁndings provide valuable information for the 
treatment of SS patients.
　 Here we evaluated whether the intravenous admin-
istration of calcium aﬀects the hemodynamics and 
outcomes of SS patients.  Why is the ionized calcium 
concentration reduced among septic patients,  and is 
this reduction associated with the severity of their 
disease and their mortality? Although the deﬁnitive 
mechanism underlying hypocalcemia in septic patients 
is unclear,  their hypocalcemia might be partly explained 
by hypoparathyroidism,  vitamin D deﬁciency,  resis-
tance to parathyroid hormone or activated vitamin D,  
or calcium inﬂux into the cells and tissues [12].  
Cardiovascular dysfunction,  caused by the depression 
of myocardial contractility and the loss of vascular 
tonus,  occasionally occurs in septic patients [24,  
25].  The relationship between ionized hypocalcemia 
and cardiovascular dysfunction is still contentious,  but 
it is speculated that cardiovascular dysfunction in 
septic patients is caused not by ionized hypocalcemia 
alone,  but by complex processes mediated by many 
factors (e.g.,  tumor necrosis factor,  interleukin 1,  
platelet-activating factor,  oxygen free radicals,  and 
nitric oxide) [26,  27].
　 In this study,  we found that the changes in the VIS 
at 1h from baseline were signiﬁcantly greater in the 
calcium-treated group than in the noncalcium-treated 
group.  The results of previous studies that assessed 
the hemodynamics of septic patients treated with or 
without calcium are controversial.  The continuous 
administration of intravenous calcium increased the 
mean arterial pressure in septic rats for only 15min 
[10].  Although the mechanism that causes intrave-
nous calcium to aﬀect the cardiovascular systems of 
septic patients only temporarily remains unclear,  the 
results of that animal study [10] are consistent with 
ours in terms of the temporal eﬀects of calcium.  
However,  in contrast to our results,  the eﬀect on the 
cardiovascular system was positive.
　 A human study demonstrated that the administra-
tion of calcium was not associated with signiﬁcant 
changes in the ﬂow,  ﬁlling pressures,  or systemic or 
pulmonary vascular resistance in septic patients [28].  
In other studies,  calcium inﬂux into cells resulted in 
elevated intracellular calcium concentrations in septic 
patients,  and this elevation was associated with cell 
dysfunction and death [29-31].
　 In the present study,  the secondary outcomes,  
including the lengths of ICU and hospital stays,  in-
hospital deaths,  28-day deaths,  and changes in the 
SOFA score at 72h from ICU admission did not diﬀer 
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signiﬁcantly between the 2 groups.  Importantly,  the 
guidelines for the management of severe sepsis and 
septic shock do not refer to the administration of cal-
cium to SS patients [6,  23].  A recent systematic 
review concluded that there was no evidence to sup-
port the treatment of critically ill patients for 
hypocalcemia [13].  The results of our study support 
this conclusion.
　 Moreover,  an observational study of 870 septic 
patients revealed that calcium administration was 
associated with an increased risk of death,  a signiﬁ-
cantly increased risk of renal dysfunction,  and a sig-
niﬁcant reduction in ventilator-free days [32].  
However,  there are still few data on the eﬀects of 
calcium administration to septic patients,  and large 
observational studies or randomized controlled trials 
that investigate the eﬀects of calcium administration 
on SS patients are required to conﬁrm our results.
　 This study had some inherent limitations.  First,  it 
was conducted retrospectively,  and there was poten-
tial selection bias.  For example,  intravenous calcium 
was administered to SS patients based on the judge-
ment of the attending physicians and/or intensivists.  
In addition,  we did not investigate the method of 
administration or the target concentration of calcium.  
Second,  although the SS patients in this study were 
treated according to the guidelines for the manage-
ment of severe sepsis and septic shock [6,  16,  17],  
there was no standard protocol for administering the 
catecholamine (e.g.,  type,  timing,  and dose).  Third,  
we did not assess the inﬂuence of factors associated 
with calcium homeostasis,  such as magnesium deple-
tion,  hypoparathyroidism,  and vitamin D deﬁciency 
[12].  Finally,  unmeasured confounding factors might 
have inﬂuenced the association between the adminis-
tration of calcium and the outcomes measured here.
　 In this retrospective single-center observational 
study,  we demonstrated that the change in the VIS of 
SS patients at 1h from baseline was signiﬁcantly 
greater in the calcium-treated patients than in the 
noncalcium-treated patients,  which suggests that the 
administration of calcium to SS patients has a delete-
rious eﬀect on their hemodynamic stabilization for a 
short time after its administration.  Large observa-
tional studies or randomized controlled trials are 
essential to verify the eﬀects of calcium administra-
tion on SS patients and to test our results.
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